Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy
- 1 May 2014
- journal article
- review article
- Published by Elsevier in Clinical Oncology
- Vol. 26 (5) , 257-265
Abstract
No abstract availableKeywords
Funding Information
- Head and Neck CR UK Programme Grant (A13407)
- NIHR RM/ICR Biomedical Research Centre
This publication has 89 references indexed in Scilit:
- Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerBreast Cancer Research and Treatment, 2012
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugsMolecular Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The ATR barrier to replication-born DNA damageDNA Repair, 2010
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialInvestigational New Drugs, 2010
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage responseDNA Repair, 2009
- Death through a tragedy: mitotic catastropheCell Death & Differentiation, 2008
- Multiple Mechanisms Control Chromosome Integrity after Replication Fork Uncoupling and Restart at Irreparable UV LesionsMolecular Cell, 2006